<DOC>
	<DOCNO>NCT00369577</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Staccato Loxapine treatment acute agitation schizophrenic patient . The study conduct 120 agitated schizophrenic patient - either newly admit hospital set research unit acute agitation already hospital chronic underlying condition . Patients meet entry criterion randomize one two dos Staccato Loxapine Staccato Placebo . Following administration study drug , assessment agitation state conduct serial time point use standard agitation scale 24 hour period .</brief_summary>
	<brief_title>StaccatoTM Loxapine Inhalation Schizophrenic Patients With Agitation .</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<criteria>1 . Male female patient age 18 65 year , inclusive . 2 . Patients meet DSMIV criterion schizophrenia , schizophreniform disorder , schizoaffective disorder . 3 . Patients judge clinically agitate Baseline total score ≥ 14 5 item ( poor impulse control , tension , hostility , uncooperativeness , excitement ) comprise PANSS Excited Component ( PEC ) . 4 . Patients value ≥ 4 ( 7 ) least 1 5 item PANSS Excited Component . 5 . Patients read understand English provide write informed consent . 6 . Patients good general health prior study participation determine detailed medical history , physical examination , 12lead ECG , blood chemistry profile , hematology , urinalysis opinion Principal Investigator . 7 . Female participant , childbearing potential sexually active , male participant , sexually active partner childbearing potential , agree use medically acceptable effective birth control method throughout study one week follow end study . Medically acceptable method contraception may use participant and/or his/her partner include abstinence , birth control pills patch , diaphragm spermicide , intrauterine device ( IUD ) , condom foam spermicide , vaginal spermicidal suppository , surgical sterilization progestin implant injection . Prohibited method include : rhythm method , withdrawal , condoms alone , diaphragm alone . 1 . Patients agitation cause acute intoxication must exclude . Positive identification nonprescription drug urine screen excludes subject . 2 . Patients treat benzodiazepine hypnotic oral shortacting intramuscular antipsychotic within 4 hour prior study drug administration must exclude . 3 . Patients treat injectable depot neuroleptic within one dose interval prior study drug administration must exclude . 4 . Patients history allergic reaction loxapine amoxapine must exclude . 5 . Female patient positive pregnancy test screen breastfeeding must exclude . 6 . Patients Parkinson 's disease , hydrocephalus , seizure disorder , history significant head trauma must exclude . 7 . Patients laboratory ECG abnormality consider clinically significant investigator qualify designee would clinical implication patient 's participation study must exclude . 8 . Patients serious unstable illness include current hepatic , renal , gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease congestive heart failure ) , endocrinologic , neurologic ( include stroke , transient ischemic attack , subarachnoidal bleeding , brain tumor , encephalopathy , meningitis ) , hematologic disease must exclude . 9 . Patients history acute chronic pulmonary disease precludes administration Staccato Loxapine ( asthma , bronchitis , emphysema ) must exclude . 10 . Patients receive investigational drug within 30 day prior current agitation episode must exclude . 11 . Patients consider investigator , reason , unsuitable candidate receiving loxapine , unable use inhalation device , must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Agitation</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>